Cargando…

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation

Background: Protease-activated receptor 1 (PAR1) and toll-like receptors (TLRs) are inflammatory mediators contributing to atherogenesis and atherothrombosis. Vorapaxar, which selectively antagonizes PAR1-signaling, is an approved, add-on antiplatelet therapy for secondary prevention. The non-hemost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friebel, Julian, Moritz, Eileen, Witkowski, Marco, Jakobs, Kai, Strässler, Elisabeth, Dörner, Andrea, Steffens, Daniel, Puccini, Marianna, Lammel, Stella, Glauben, Rainer, Nowak, Franziska, Kränkel, Nicolle, Haghikia, Arash, Moos, Verena, Schutheiss, Heinz-Peter, Felix, Stephan B., Landmesser, Ulf, Rauch, Bernhard H., Rauch, Ursula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700178/ https://www.ncbi.nlm.nih.gov/pubmed/34944024 http://dx.doi.org/10.3390/cells10123517

Ejemplares similares

The Role of NETosis and Complement Activation in COVID-19-Associated Coagulopathies
por: Ghanbari, Emily Parissa, et al.
Publicado: (2023)

Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19
por: Puccini, Marianna, et al.
Publicado: (2023)

Cytotoxic CD8(+) T Cells Are Involved in the Thrombo-Inflammatory Response during First-Diagnosed Atrial Fibrillation
por: Friebel, Julian, et al.
Publicado: (2022)

Disease Severity in Moderate-to-Severe COVID-19 Is Associated With Platelet Hyperreactivity and Innate Immune Activation
por: Jakobs, Kai, et al.
Publicado: (2022)

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
por: Puccini, Marianna, et al.
Publicado: (2022)

Adenine Nucleotide Translocase 1 Expression Modulates the Immune Response in Ischemic Hearts
por: Yergöz, Fatih, et al.
Publicado: (2021)

Intestinal Barrier Dysfunction and Microbial Translocation in Patients with First-Diagnosed Atrial Fibrillation
por: Blöbaum, Leon, et al.
Publicado: (2023)

Micro–RNA-126 Reduces the Blood Thrombogenicity in Diabetes Mellitus via Targeting of Tissue Factor
por: Witkowski, Marco, et al.
Publicado: (2016)

Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
por: Puccini, Marianna, et al.
Publicado: (2022)

MicroRNA-19a contributes to the epigenetic regulation of tissue factor in diabetes
por: Witkowski, Marco, et al.
Publicado: (2018)

Artificial sweetener sucralose: a possible modulator of autoimmune diseases
por: Kränkel, Nicolle, et al.
Publicado: (2023)

Metformin Is Associated with Reduced Tissue Factor Procoagulant Activity in Patients with Poorly Controlled Diabetes
por: Witkowski, Marco, et al.
Publicado: (2020)

Age Is Relative—Impact of Donor Age on Induced Pluripotent Stem Cell-Derived Cell Functionality
por: Strässler, Elisabeth Tamara, et al.
Publicado: (2018)

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes
por: Witkowski, Marco, et al.
Publicado: (2020)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
por: Olie, Renske H., et al.
Publicado: (2019)

Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial
por: Rauch-Kröhnert, Ursula, et al.
Publicado: (2023)

Effects of Apolipoprotein A-I/High-Density Lipoprotein Cholesterol on Atherosclerotic Vascular Disease: Critical Impact of Atherosclerosis Disease Stage and Disease Milieu?
por: Haghikia, Arash, et al.
Publicado: (2018)

Gliflozine – in Zukunft Kardioprotektiva?
por: Rauch-Kröhnert, Ursula, et al.
Publicado: (2021)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

Adenine Nucleotide Translocase 1 Expression Is Coupled to the HSP27-Mediated TLR4 Signaling in Cardiomyocytes
por: Winter, Julia, et al.
Publicado: (2019)

Impact of the Gut Microbiota on Atorvastatin Mediated Effects on Blood Lipids
por: Zimmermann, Friederike, et al.
Publicado: (2020)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
por: White, Harvey D., et al.
Publicado: (2014)

Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar
por: Cheng, Judy WM
Publicado: (2016)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study
por: Schuette, Claudia, et al.
Publicado: (2015)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
por: Farag, Mohamed, et al.
Publicado: (2015)

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
por: Kraft, WK, et al.
Publicado: (2016)

You can teach an old dog new tricks: angiopoietin-1 instructs Tie2(pos) myeloid cells to promote neovascularization in ischemic limbs
por: Emanueli, Costanza, et al.
Publicado: (2013)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
por: Ungar, Leo, et al.
Publicado: (2018)

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
por: van Diepen, Sean, et al.
Publicado: (2015)

Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)
por: Schwarz, Andrea, et al.
Publicado: (2022)

The Dynamic of Extracellular Vesicles in Patients With Subacute Stroke: Results of the “Biomarkers and Perfusion—Training-Induced Changes After Stroke” (BAPTISe) Study
por: Jödicke, Ruben A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0v0rmrdfr7aju3hgaapvfg2h8n